| Year |
Citation |
Score |
| 2024 |
Mog BJ, Marcou N, DiNapoli SR, Pearlman AH, Nichakawade TD, Hwang MS, Douglass J, Hsiue EH, Glavaris S, Wright KM, Konig MF, Paul S, Wyhs N, Ge J, Miller MS, et al. Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities. Science Translational Medicine. 16: eadg7123. PMID 38985855 DOI: 10.1126/scitranslmed.adg7123 |
0.752 |
|
| 2023 |
Wright KM, DiNapoli SR, Miller MS, Aitana Azurmendi P, Zhao X, Yu Z, Chakrabarti M, Shi W, Douglass J, Hwang MS, Hsiue EH, Mog BJ, Pearlman AH, Paul S, Konig MF, et al. Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen. Nature Communications. 14: 5063. PMID 37604828 DOI: 10.1038/s41467-023-40821-w |
0.767 |
|
| 2021 |
Hwang MS, Miller MS, Thirawatananond P, Douglass J, Wright KM, Hsiue EH, Mog BJ, Aytenfisu TY, Murphy MB, Aitana Azurmendi P, Skora AD, Pearlman AH, Paul S, DiNapoli SR, Konig MF, et al. Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. Nature Communications. 12: 5271. PMID 34489470 DOI: 10.1038/s41467-021-25605-4 |
0.768 |
|
| 2021 |
Hsiue EH, Wright KM, Douglass J, Hwang MS, Mog BJ, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Wang Q, Schaefer A, Miller MS, Skora AD, Azurmendi PA, Murphy MB, et al. Targeting a neoantigen derived from a common mutation. Science (New York, N.Y.). PMID 33649166 DOI: 10.1126/science.abc8697 |
0.768 |
|
| 2021 |
Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, Miller MS, Wright KM, Azurmendi PA, Wang Q, Paul S, Schaefer A, Skora AD, Molin MD, Konig MF, et al. Bispecific antibodies targeting mutant neoantigens. Science Immunology. 6. PMID 33649101 DOI: 10.1126/sciimmunol.abd5515 |
0.77 |
|
| 2019 |
Miller MS, Douglass J, Hwang MS, Skora AD, Murphy M, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S, Gabelli SB. An engineered antibody fragment targeting mutant β-catenin via Major Histocompatibility Complex I neoantigen presentation. The Journal of Biological Chemistry. PMID 31690625 DOI: 10.1074/Jbc.Ra119.010251 |
0.698 |
|
| 2019 |
Miller MS, Thompson PE, Gabelli SB. Structural Determinants of Isoform Selectivity in PI3K Inhibitors. Biomolecules. 9. PMID 30813656 DOI: 10.3390/biom9030082 |
0.612 |
|
| 2019 |
Miller MS, Maheshwari S, Shi W, Gao Y, Chu N, Soares AS, Cole PA, Amzel LM, Fuchs MR, Jakoncic J, Gabelli SB. Getting the Most Out of Your Crystals: Data Collection at the New High-Flux, Microfocus MX Beamlines at NSLS-II. Molecules (Basel, Switzerland). 24. PMID 30704096 DOI: 10.3390/Molecules24030496 |
0.69 |
|
| 2017 |
Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, Kumar D, Gabrielson M, Pomper MG, Gabelli SB, Nimmagadda S. Corrigendum to "Rapid PD-L1 detection in tumors with PET using a highly specific peptide" [Biochemical and Biophysical Research Communications 483/1 (2017) 258-263]. Biochemical and Biophysical Research Communications. PMID 28801167 DOI: 10.1016/J.Bbrc.2017.08.001 |
0.517 |
|
| 2017 |
Maheshwari S, Miller MS, O'Meally R, Cole RN, Amzel LM, Gabelli SB. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition. The Journal of Biological Chemistry. PMID 28676499 DOI: 10.1074/Jbc.M116.772426 |
0.714 |
|
| 2017 |
Miller MS, Maheshwari S, McRobb FM, Kinzler KW, Amzel LM, Vogelstein B, Gabelli SB. Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design. Bioorganic & Medicinal Chemistry. PMID 28129991 DOI: 10.1016/J.Bmc.2017.01.012 |
0.725 |
|
| 2016 |
Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, Kumar D, Gabrielson M, Pomper MG, Gabelli SB, Nimmagadda S. Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochemical and Biophysical Research Communications. PMID 28025143 DOI: 10.1016/J.Bbrc.2016.12.156 |
0.519 |
|
| 2015 |
Schepers D, Doyle AJ, Oswald G, Sparks E, Myers L, Willems PJ, Mansour S, Simpson MA, Frysira H, Maat-Kievit A, Van Minkelen R, Hoogeboom JM, Mortier GR, Titheradge H, Brueton L, ... ... Miller M, et al. The SMAD-binding domain of SKI: a hotspot for de novo mutations causing Shprintzen-Goldberg syndrome. European Journal of Human Genetics : Ejhg. 23: 224-8. PMID 24736733 DOI: 10.1038/Ejhg.2014.61 |
0.346 |
|
| 2015 |
Miller M, Schmidt-Kittler O, Bolduc DM, Brower ET, Chaves-Moreira D, Allaire M, Kinzler KW, Jennings IG, Thompson PE, Cole PA, Amzel LM, Vogelstein B, Gabelli SB. Abstract PR02: Targeting PI3K: The PIP2 binding site Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Pr02 |
0.745 |
|
| 2014 |
Miller MS, Schmidt-Kittler O, Bolduc DM, Brower ET, Chaves-Moreira D, Allaire M, Kinzler KW, Jennings IG, Thompson PE, Cole PA, Amzel LM, Vogelstein B, Gabelli SB. Structural basis of nSH2 regulation and lipid binding in PI3Kα. Oncotarget. 5: 5198-208. PMID 25105564 DOI: 10.18632/Oncotarget.2263 |
0.728 |
|
| 2014 |
Miller MS, Schmidt-Kittler O, Bolduc DM, Brower ET, Chaves-Moreira D, Allaire M, Kinzler KW, Jennings IG, Thompson PE, Cole PA, Amzel LM, Vogelstein B, Gabelli SB. Structural basis of nSH2 regulation and lipid binding in PI3Kα Oncotarget. 5: 5198-5208. |
0.686 |
|
| 2013 |
Zhang F, Bhat S, Gabelli SB, Chen X, Miller MS, Nacev BA, Cheng YL, Meyers DJ, Tenney K, Shim JS, Crews P, Amzel LM, Ma D, Liu JO. Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells Journal of Medicinal Chemistry. 56: 3996-4016. PMID 23634668 DOI: 10.1021/Jm400227Z |
0.658 |
|
| Show low-probability matches. |